GLP-1 News & Updates
Daily summaries of the most important GLP-1 stories — FDA decisions, clinical research, telehealth updates, and insurance coverage changes.
Today — Friday, May 22, 2026
4 articlesGLP-1 Drugs Cut Heart Attack and Stroke Risk by 13%, Major Review Finds
TLDR: A systematic review of 11 major cardiovascular outcome trials involving over 90,000 patients found that GLP-1 receptor agonists reduced the risk of heart attacks, strokes, and cardiovascular death by about 13%. Researchers at Anglia Ruskin University found the benefits held regardless of whether patients had diabetes, and all-cause mortality was also lower. The findings were published in Cardiovascular Diabetology – Endocrinology Reports.
Read full story →Oral GLP-1 Pill Helps Patients Maintain 75–80% of Weight Loss After Stopping Injectables
TLDR: The ATTAIN-MAINTAIN trial found that patients who switched from injectable GLP-1s (tirzepatide or semaglutide) to the oral pill orforglipron maintained 75–80% of their weight loss over 52 weeks. Led by Weill Cornell Medicine and NewYork-Presbyterian, the phase 3b trial enrolled 376 patients and was published May 12 in Nature Medicine. The pill was well-tolerated, with only mild to moderate GI side effects.
Read full story →FDA Proposes Removing Semaglutide, Tirzepatide, and Liraglutide from 503B Compounding List
TLDR: The FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. The move would effectively end large-scale compounding of GLP-1 medications at most facilities, with a public comment period closing June 29, 2026. If finalized, the already-reduced supply of compounded GLP-1s would drop sharply.
Read full story →Medicare Launches Bridge Program to Lower GLP-1 Co-Pays for Seniors
TLDR: The Trump administration has rolled out a Medicare bridge program designed to reduce out-of-pocket GLP-1 costs for eligible seniors, creating a new pathway to coverage for obesity drugs like Wegovy and Zepbound. Medicare has historically excluded weight-loss drugs, and the pilot program is being watched closely as a potential model for broader coverage expansion. Details on eligibility and co-pay levels are still being finalized.
Read full story →Yesterday — Thursday, May 21, 2026
4 articlesFDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from 503B Compounding List
TLDR: The FDA announced it is proposing to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound these drugs from bulk substances. The move effectively moves to close the door permanently on large-scale compounding of these GLP-1 medications. Public comments are open through June 29, 2026.
Read full story →Oral GLP-1 Pill Orforglipron Helps Patients Keep Weight Off After Stopping Injectables
TLDR: A phase 3b clinical trial (ATTAIN-MAINTAIN) found that switching from injectable GLP-1s to once-daily oral orforglipron helped patients maintain roughly 75-80% of their prior weight loss over 52 weeks. The study, published in Nature Medicine, is the first to examine longer-term weight maintenance using an oral GLP-1 after injectable therapy and offers a potential new option for patients who want to avoid injections.
Read full story →Semaglutide Delivers Major Weight Loss in Adults Over 65, Large Analysis Finds
TLDR: A pooled analysis of six STEP clinical trials found that semaglutide produced an average body weight reduction of 15.4% in adults over age 65 with obesity — nearly triple the 5.1% seen with placebo. Presented at ECO 2026, the findings support the use of GLP-1 therapy in older adults, a population where obesity-related complications are especially prevalent.
Read full story →Medicare GLP-1 Bridge Program to Launch July 2026 with $50 Monthly Copay
TLDR: CMS has finalized the Medicare GLP-1 Bridge, a short-term coverage demonstration running July 1, 2026 through December 31, 2027. Eligible Medicare Part D beneficiaries can access Wegovy, Zepbound, and Foundayo for a flat $50 monthly copay, with CMS covering the remaining cost. The program has been extended through 2027 following adjustments by the Trump administration.
Read full story →Wednesday — Wednesday, May 20, 2026
4 articlesGreater Weight Loss on GLP-1s Dramatically Cuts Risk of Sleep Apnea, Kidney Disease, and Heart Failure
TLDR: A real-world study of nearly 90,000 patients found that those who lost 15% or more of their BMI on GLP-1 medications had a 69% lower risk of sleep apnea, 37% lower risk of osteoarthritis, and 30% lower risk of chronic kidney disease. Presented at ECO 2026, the findings underscore the clinical value of sustained weight loss. Roughly half of all patients discontinued treatment within one year.
Read full story →Switching from Injectable GLP-1 to Orforglipron Pill Preserves Most Weight Loss, Phase 3 Trial Finds
TLDR: The ATTAIN-MAINTAIN trial showed that patients who switched from injectable semaglutide or tirzepatide to Lilly's oral orforglipron (Foundayo) maintained 75-80% of their weight loss over 52 weeks. Published May 12 in Nature Medicine, the results position orforglipron as a practical long-term maintenance option for patients who want to avoid ongoing injections.
Read full story →FDA Proposes Permanent Ban on Bulk Compounding of Semaglutide and Tirzepatide
TLDR: The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which would permanently bar outsourcing facilities from compounding these drugs from bulk ingredients. The public comment period closes June 29, 2026. The move follows more than 455 adverse event reports linked to compounded semaglutide products.
Read full story →Medicare to Launch $50/Month GLP-1 Weight Loss Drug Bridge Program Starting July 2026
TLDR: CMS announced that Medicare Part D beneficiaries will gain access to GLP-1 weight loss drugs for a $50 monthly copay starting July 1, 2026, through December 2027. The temporary bridge program represents a major shift in coverage for millions of Medicare enrollees and is intended to bridge the gap before permanent coverage decisions are finalized.
Read full story →Tuesday — Tuesday, May 19, 2026
3 articlesOral GLP-1 Pill Helps Patients Maintain Weight Loss After Stopping Injectables
TLDR: The ATTAIN-MAINTAIN phase 3b trial, published May 12 in Nature Medicine, found that switching from injectable GLP-1s (semaglutide or tirzepatide) to the once-daily oral pill orforglipron helped patients preserve 75-80% of their prior weight loss. It is the first study to examine long-term weight maintenance using an oral GLP-1 after discontinuing injectables.
Read full story →FDA Proposes Permanently Banning Bulk Compounding of Semaglutide and Tirzepatide
TLDR: On April 30, 2026, the FDA announced a proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which governs what outsourcing facilities can compound at scale. If finalized after a public comment period closing June 29, the move would effectively shut down the large-scale compounded GLP-1 market, leaving only limited 503A pharmacy pathways for individual patients.
Read full story →NIH Study: Oral GLP-1 Drugs Reach Deep Brain Reward Circuits to Curb Pleasure Eating
TLDR: An NIH-funded study published in Nature found that oral small-molecule GLP-1 receptor agonists like orforglipron activate the central amygdala — a brain region associated with desire — reducing dopamine release and suppressing hedonic (pleasure-driven) eating. The mechanism is distinct from how injectable GLP-1s work, and researchers say it could eventually inform treatments for substance use disorder.
Read full story →Monday — Monday, May 18, 2026
5 articlesOral GLP-1 Drug Orforglipron Helps Maintain Weight Loss After Injectable Therapy, ATTAIN-MAINTAIN Trial Finds
TLDR: A phase 3b clinical trial published in Nature Medicine found that switching from injectable GLP-1s (semaglutide or tirzepatide) to the once-daily oral pill orforglipron helped patients maintain 75-80% of their weight loss. The ATTAIN-MAINTAIN trial is the first study to examine long-term weight maintenance using an oral GLP-1 after an injectable.
Read full story →FDA Proposes Permanently Removing Semaglutide and Tirzepatide From 503B Compounding Bulks List
TLDR: The FDA has proposed excluding compounded semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, citing no clinical need for bulk compounding when FDA-approved versions are available. If finalized, outsourcing facilities would no longer be able to produce these drugs at scale, with a public comment period closing June 29, 2026.
Read full story →Novo Nordisk Q1 2026: Wegovy Pill Surpasses Analyst Estimates With 1.3 Million Prescriptions
TLDR: Novo Nordisk reported Q1 2026 earnings showing Wegovy injectable sales up 12% year-on-year, while its new oral Wegovy pill generated 2.26 billion kroner in sales — well above analyst estimates — with approximately 1.3 million prescriptions in its first full quarter in the US.
Read full story →NIH Study: Oral Small-Molecule GLP-1 Drugs Penetrate Deep Into Brain to Suppress Pleasure Eating
TLDR: An NIH-funded study found that oral small-molecule GLP-1 receptor agonists like orforglipron suppress hedonic (pleasure-driven) eating by modulating reward circuits deep in the brain — a mechanism distinct from injectable GLP-1s. The finding may explain why this new class of cheaper, pill-based GLP-1s produces meaningful weight loss.
Read full story →CMS Launches BALANCE Model to Expand Medicaid and Medicare Access to GLP-1 Medications
TLDR: The Centers for Medicare and Medicaid Services announced the BALANCE voluntary payment model, launching in Medicaid as early as May 2026 and in Medicare Part D in January 2027, to expand patient access to GLP-1 weight-loss medications while helping control program costs.
Read full story →Sunday — Sunday, May 17, 2026
4 articlesNIH Study: Oral GLP-1 Drugs Suppress Pleasure Eating by Activating Deep Brain Reward Circuit
TLDR: NIH-funded researchers found that oral small-molecule GLP-1 drugs like orforglipron activate the central amygdala—a brain region associated with reward and deeper than previously believed GLP-1s could reach—reducing dopamine release during pleasure-driven eating in mice. This mechanism is distinct from the appetite-suppression pathways targeted by injectable GLP-1s and may have future relevance for treating substance use disorders.
Read full story →Medicare to Cover Wegovy and Zepbound at $50/Month Starting July 2026 Through New Bridge Program
TLDR: Medicare Part D beneficiaries with obesity who meet clinical criteria will be able to access Wegovy and Zepbound at a $50/month copay starting July 1, 2026, through the Medicare GLP-1 Bridge program. CMS secured $245/month net pricing from Novo Nordisk and Eli Lilly, and the program has been extended through 2027 after the broader BALANCE Model was shelved for Medicare.
Read full story →GLP-1 Receptor Agonists Linked to Lower Heart Attack and Kidney Disease Risk in Type 1 Diabetes Patients
TLDR: A Nature Medicine study found that people with type 1 diabetes taking GLP-1 receptor agonists had approximately 15% lower risk of major cardiovascular events and 19% lower risk of end-stage kidney disease compared to those not on the drugs. The findings extend GLP-1 cardiovascular evidence to a population historically excluded from major obesity trials, with no significant new safety signals identified.
Read full story →Federal BALANCE Model Begins Expanding GLP-1 Obesity Coverage in State Medicaid Programs
TLDR: A federal demonstration program called BALANCE began rolling out to state Medicaid programs on May 1, 2026, expanding GLP-1 drug coverage for obesity treatment in participating states. The model offers negotiated drug prices and requires manufacturers to provide lifestyle support programs alongside prescriptions. States have until July 31, 2026 to submit their participation applications to CMS.
Read full story →Saturday — Saturday, May 16, 2026
4 articlesSemaglutide Cuts Heavy Drinking by 41% in First Major Randomized Trial
TLDR: A 26-week randomized trial in The Lancet found that once-weekly semaglutide, added to cognitive behavioral therapy, reduced heavy drinking days by 41.1% in adults with alcohol use disorder and comorbid obesity — nearly 14 percentage points more than CBT alone. Participants on semaglutide averaged 5 heavy drinking days per month versus 9 in the placebo group, the strongest pharmacotherapy signal recorded for alcohol use disorder. The results add weight to the theory that GLP-1 receptors modulate addiction and reward pathways beyond food.
Read full story →Novo Nordisk Q1 2026: Wegovy Pill Earns $355M in Debut Quarter as Company Raises Guidance
TLDR: Novo Nordisk Q1 2026 results showed the oral Wegovy pill generating $355M in its first full quarter with 1.3 million prescriptions, while injectable Wegovy rose 12% year-over-year and Ozempic fell 8% but beat expectations. Overall sales jumped 32% to roughly $15.2B, prompting Novo to raise full-year guidance. Wegovy now holds 65% of all new U.S. obesity prescriptions, giving Novo a lead over rival Eli Lilly in the fast-growing oral GLP-1 market.
Read full story →Study Finds GLP-1 Drugs Do Not Cause Abnormal Muscle Loss Despite Weight Reduction
TLDR: A study in Cell Reports Medicine found that GLP-1 medicines did not cause disproportionate or pathological muscle loss in obese mice or humans — absolute lean mass declined as part of overall weight loss, but relative muscle strength and physical function were preserved or improved. Much of the apparent lean mass reduction was traced to liver fat loss rather than skeletal muscle. The findings challenge widespread fears about Ozempic-induced muscle wasting and suggest body composition changes mirror those seen with conventional caloric restriction.
Read full story →FDA Reviewing Novo Nordisk CagriSema NDA; Decision Expected October 2026
TLDR: The FDA is actively reviewing Novo Nordisk's NDA for CagriSema — a once-weekly combination of semaglutide 2.4mg and amylin analog cagrilintide — with a regulatory decision expected around October 2026. In the REDEFINE 1 trial, CagriSema produced 22.7% mean weight loss at 68 weeks, roughly 8 percentage points more than semaglutide alone and without an apparent weight loss plateau. Approval would make CagriSema the first GLP-1/amylin combination drug and a potentially more potent option than existing injectables.
Read full story →Friday — Friday, May 15, 2026
4 articlesOral GLP-1 Pill Maintains 75-80% of Weight Loss After Injectable Therapy, Phase 3 Trial Finds
TLDR: The ATTAIN-MAINTAIN phase 3b trial, published in Nature Medicine on May 12, found that patients who switched from injectable semaglutide or tirzepatide to daily oral orforglipron maintained 75-80% of their prior weight loss over 52 weeks. The pill was well tolerated, with only mild to moderate gastrointestinal side effects, offering a promising injection-free maintenance option.
Read full story →Semaglutide Drives 15% Weight Loss in Adults Over 65, Pooled Analysis Shows
TLDR: A pooled analysis presented at ECO 2026 found that semaglutide 2.4 mg produced a 15.4% reduction in body weight for adults 65 and older after 68 weeks, compared to just 5.1% with placebo. Over two-thirds of treated participants lost at least 10% of their body weight, though serious adverse events were more common in the drug group.
Read full story →FDA Proposes Permanent Ban on Bulk Compounding of Semaglutide and Tirzepatide
TLDR: The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which would permanently end outsourcing-facility compounding of these drugs. The agency cited no demonstrated clinical need given the availability of FDA-approved brand-name versions, with a public comment period open through June 29, 2026.
Read full story →Ozempic Linked to Lower Risk of Depression and Anxiety in New Research
TLDR: A new study finds that people taking semaglutide-based drugs like Ozempic show significantly reduced rates of depression, anxiety, and addiction compared to those not on the medication. The findings add to growing evidence that GLP-1 receptor agonists may carry broad neuropsychiatric benefits well beyond weight loss.
Read full story →Wednesday — Wednesday, May 13, 2026
4 articlesOral GLP-1 Orforglipron Maintains Most Weight Loss After Injectables, Study Finds
TLDR: A new clinical trial (ATTAIN-MAINTAIN) found that patients who switched from injectable GLP-1s to oral orforglipron maintained 74–79% of their weight loss, compared to just 37–49% in the placebo group. Led by Weill Cornell Medicine and NewYork-Presbyterian, it is the first study examining long-term weight maintenance using an oral GLP-1 after injectable therapy.
Read full story →FDA Proposes Permanently Banning Large-Scale Compounding of Semaglutide and Tirzepatide
TLDR: The FDA announced it intends to remove semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, effectively ending large-scale compounding of these GLP-1 medications. The agency found no clinical need for compounded versions now that brand-name supplies are no longer in shortage. A public comment period is open through June 29, 2026.
Read full story →Trump Administration Strikes MFN Pricing Deals with Lilly and Novo Nordisk to Lower GLP-1 Costs
TLDR: The Trump administration reached Most-Favored-Nation pricing agreements with Eli Lilly and Novo Nordisk, capping injectable GLP-1 medications at $245 per month for Medicare patients. A Medicare GLP-1 Bridge program launching July 1, 2026 will give Part D beneficiaries access to anti-obesity GLP-1s at a flat $50 monthly copay.
Read full story →Louisiana Bill Would Expand Medicaid Access to GLP-1 Weight Loss Drugs
TLDR: Louisiana lawmakers are considering Senate Bill 433, which would grant Medicaid recipients access to GLP-1 medications like Ozempic, Wegovy, and Mounjaro for obesity treatment. The bill comes as Louisiana grapples with an adult obesity rate of nearly 40%, one of the highest in the nation.
Read full story →Tuesday — Tuesday, May 12, 2026
4 articlesFDA Proposes Removing Semaglutide and Tirzepatide from Bulk Compounding List
TLDR: The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk compounding list on April 30, finding no clinical need for large-scale compounding of these drugs. The move would effectively end mass production of lower-cost compounded GLP-1s unless an official drug shortage is declared, with public comments accepted through June 2026.
Read full story →Medicare to Cover Wegovy and Zepbound for $50/Month Starting July 2026
TLDR: The Medicare GLP-1 Bridge program will provide coverage for Wegovy and Zepbound to eligible Part D beneficiaries at a $50 monthly copay beginning July 1, 2026, serving as a bridge until a longer-term program could begin in 2028. CMS also confirmed it is not moving forward with the BALANCE Model in 2027 following the Trump administration review.
Read full story →NIH Study: Oral Small-Molecule GLP-1 Drugs Penetrate Deep Brain Reward Circuits
TLDR: NIH-funded researchers found that oral small-molecule GLP-1 receptor agonists activate the central amygdala — deeper in the brain than scientists previously thought GLP-1s could reach. Once activated, this region reduces dopamine release into the brain reward circuitry during hedonic eating, offering a new explanation for how these drugs curb cravings.
Read full story →GLP-1 Drug Availability Update: Tirzepatide Still on Shortage List in May 2026
TLDR: As of May 2026, Ozempic is broadly available at most pharmacies while certain 2 mg doses may see intermittent delays. Tirzepatide (Mounjaro, Zepbound) remains on the FDA shortage list at select dose strengths, which continues to allow compounding — even as the FDA moves to restrict bulk compounding for semaglutide.
Read full story →Monday — Monday, May 11, 2026
4 articlesFDA Proposes to Permanently Exclude Semaglutide and Tirzepatide from 503B Compounding
TLDR: The FDA announced a proposal on April 30, 2026 to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list, meaning outsourcing facilities could be permanently barred from compounding these drugs from bulk substances. The agency cited no clinical need and flagged over 455 adverse event reports tied to compounded semaglutide. A public comment period runs through June 29, 2026.
Read full story →Medicare GLP-1 Bridge Program Offers $50/Month Access to Wegovy and Zepbound Starting July 2026
TLDR: CMS announced a Medicare GLP-1 Bridge program running July 1, 2026 through December 31, 2027, giving eligible Medicare Part D enrollees access to Wegovy and Zepbound for a flat $50 monthly copay. The copay does not increase with higher doses and does not count toward the annual out-of-pocket cap, though low-income subsidy protections will not apply.
Read full story →Ozempic Lawsuits Surpass 3,000 Cases Over Vision Loss and Gastroparesis Claims
TLDR: More than 3,000 product liability lawsuits are pending against Novo Nordisk tied to Ozempic and Wegovy, focused on gastroparesis and non-arteritic anterior ischemic optic neuropathy. The WHO issued a warning in 2025 linking semaglutide to rare optic nerve injury affecting roughly 1 in 10,000 users, and research found semaglutide the only drug strongly associated with the condition in a review of 30 million FDA adverse event reports.
Read full story →GLP-1 Drugs Show Promise for Neurological Conditions Including Alzheimer's and Parkinson's
TLDR: A new review in NeurologyLive examines growing evidence that GLP-1 receptor agonists may benefit patients with Alzheimer's disease, Parkinson's disease, and sleep disorders. While results from early trials are mixed, researchers describe the outlook as promising and are calling for larger, well-designed clinical trials to establish efficacy.
Read full story →Sunday — Sunday, May 10, 2026
4 articlesMedicare Launches $50-Copay Bridge Program for GLP-1 Weight Loss Drugs Starting July 2026
TLDR: The Centers for Medicare and Medicaid Services announced a short-term pilot program running July 1, 2026 through Dec. 31, 2027 that gives Medicare beneficiaries access to FDA-approved GLP-1 weight loss drugs for a $50 monthly copay that does not increase with dose. The Bridge program covers injectable and pill formulations of Wegovy and is designed to expand access while longer-term permanent coverage rules are finalized. Advocates called it a meaningful step for the roughly 7 million seniors with obesity who currently have no coverage pathway.
Read full story →NEJM Publishes SURMOUNT-5 Results: Tirzepatide Outperforms Semaglutide With 20% vs. 14% Weight Loss Over 72 Weeks
TLDR: The landmark SURMOUNT-5 head-to-head randomized trial, now published in the New England Journal of Medicine, found that tirzepatide (Zepbound/Mounjaro) produced 20.2% mean weight loss over 72 weeks compared to 13.7% for semaglutide (Wegovy) in adults with obesity or overweight and comorbidities. Patients on tirzepatide were also significantly more likely to achieve 10%, 15%, 20%, and 25% body weight reductions. Both drugs showed similar gastrointestinal side effect profiles, mostly mild-to-moderate during dose escalation.
Read full story →Real-World Study: Tirzepatide and Semaglutide Show Similar Cardiovascular Outcomes Despite Different Weight Loss Rates
TLDR: A large trial emulation study published in Nature Medicine found that semaglutide and tirzepatide produce comparable cardiovascular benefits in patients with obesity and type 2 diabetes at elevated heart disease risk, despite tirzepatide achieving greater weight loss. The findings suggest that cardiovascular protection from GLP-1 drugs may be largely independent of the degree of weight reduction, which has significant implications for treatment decisions and insurer coverage criteria.
Read full story →ICER Releases Comprehensive Cost-Effectiveness Review of Semaglutide and Tirzepatide for Obesity
TLDR: The Institute for Clinical and Economic Review published a detailed cost-effectiveness analysis of semaglutide and tirzepatide for obesity treatment in the May 2026 issue of JMCP. The report evaluates net pricing relative to clinical benefit and long-term cost offsets from reduced cardiovascular events and diabetes complications. Findings are expected to influence payer coverage decisions and formulary negotiations for both commercial insurers and Medicare as the BALANCE payment model takes shape.
Read full story →Saturday — Saturday, May 9, 2026
4 articlesSemaglutide Use Tied to 44% Lower Depression Risk and 38% Reduction in Anxiety Disorders
TLDR: A large observational study found that people taking semaglutide-based GLP-1 medications experienced significantly fewer psychiatric hospitalizations and lower rates of depression and anxiety. Psychiatric-related hospital care and sick leave dropped by 42% during semaglutide use, with depression risk 44% lower and anxiety disorders reduced by 38%. Researchers say the findings add to growing evidence that GLP-1 drugs may have meaningful mental health benefits beyond weight loss.
Read full story →UK Regulator Warns GLP-1 Users to Watch for Signs of Pancreatitis
TLDR: The UK Medicines and Healthcare products Regulatory Agency (MHRA) issued a safety reminder for patients using Ozempic, Wegovy, and Mounjaro to be alert to symptoms of acute pancreatitis, including severe and persistent abdominal and back pain. The MHRA emphasized that while the risk is rare, swift recognition is critical as the condition can become life-threatening. Clinicians are also being asked to discuss the warning signs with patients before prescribing.
Read full story →GLP-1 Price Reality Check: Some Costs Fell Under Trump Initiatives, But Many Drugs Got More Expensive
TLDR: A new analysis finds that while the Trump administration's TrumpRx and most-favored-nation deals brought meaningful price cuts for Wegovy and Zepbound through select channels, overall drug prices rose for the majority of medications in 2026. GLP-1 patients without insurance or Medicare still face substantial out-of-pocket costs outside the direct-purchase programs. Advocates say access gaps remain significant despite headline-grabbing price announcements.
Read full story →Pediatric GLP-1 Prescriptions Rising as Adolescent Obesity Rates Drive Demand
TLDR: As GLP-1 prices gradually decrease and prescribing guidelines expand, more adolescents are receiving semaglutide and liraglutide for obesity treatment. CDC data shows that while 1 in 5 obese teenagers is eligible, fewer than 1% currently use a GLP-1 medication — but clinicians expect that number to rise. Pediatric endocrinologists note the drugs show promise for this population but say long-term safety data in adolescents is still limited.
Read full story →Friday — Friday, May 8, 2026
5 articlesFDA Proposes Permanent Ban on Compounded Semaglutide and Tirzepatide
TLDR: The FDA has proposed formally removing semaglutide, tirzepatide, and liraglutide from the list of bulk drug substances that 503B outsourcing facilities can compound. The agency declared there is no clinical need for compounded versions, opening a public comment period through June 29, 2026. If finalized, the rule would permanently close the door on the compounding industry’s mass production of GLP-1 alternatives.
Read full story →Trump Administration Announces Most-Favored-Nation Pricing Deal for GLP-1 Weight Loss Drugs
TLDR: The Trump administration struck deals with Eli Lilly and Novo Nordisk to cap Medicare GLP-1 costs at $245 per month with a $50 patient copay. Through the new TrumpRx direct platform, Wegovy and Ozempic will be available as low as $149–$350 per month depending on dose. The agreements are projected to save Medicare and Medicaid beneficiaries billions over the coming decade.
Read full story →Louisiana Bill Would Expand Medicaid Coverage of Ozempic, Wegovy, and Mounjaro
TLDR: Louisiana Senate Bill 433 would allow qualified Medicaid recipients to use GLP-1 medications to treat obesity, not just diabetes. The bill is part of a growing national trend of states pushing to broaden access to weight-loss drugs for lower-income populations. If passed, Louisiana would join a small but expanding group of states covering anti-obesity GLP-1 treatment through Medicaid.
Read full story →Study Finds Wegovy and Ozempic Linked to Optic Nerve Injury Risk — Mounjaro and Zepbound Not Implicated
TLDR: A new analysis of more than 30 million FDA adverse event reports found that semaglutide-based drugs — specifically Wegovy and Ozempic — were the only GLP-1 medications strongly associated with non-arteritic anterior ischemic optic neuropathy (NAION). Tirzepatide products Mounjaro and Zepbound did not show the same safety signal. The findings add pressure to ongoing litigation against Novo Nordisk.
Read full story →Gut Procedure May Help Patients Keep Weight Off After Stopping GLP-1 Drugs
TLDR: Researchers published the first blinded, randomized, sham-controlled evidence that duodenal mucosal resurfacing — a minimally invasive endoscopic procedure — may help patients sustain weight loss after discontinuing Ozempic or Wegovy. The findings suggest that resetting the gut lining could address the underlying metabolic dysfunction that often leads to weight regain. Experts say the results could open a new chapter in long-term obesity management.
Read full story →Thursday — Thursday, May 7, 2026
4 articlesFDA Moves to Permanently Close the Door on Compounded GLP-1s
TLDR: The FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug list, citing no clinical need for compounded versions. A public comment period is open through June 29, 2026. If finalized, the rule would effectively end large-scale GLP-1 compounding by outsourcing facilities.
Read full story →Weight Loss Drug Ozempic Linked to Lower Depression and Anxiety Risk
TLDR: A large study tracking nearly 100,000 people found that semaglutide use was associated with a 42% drop in psychiatric hospital care, 44% lower risk of depression, and 38% lower risk of anxiety disorders. The findings, published in The Lancet Psychiatry, suggest GLP-1 medications may have broad mental health benefits beyond weight loss.
Read full story →Medicare GLP-1 Bridge Program to Offer $50 Copay Starting July 2026
TLDR: CMS announced a Medicare GLP-1 Bridge program that will give eligible Part D beneficiaries access to approved GLP-1 weight loss drugs for a flat $50 monthly copay from July 1, 2026 through December 31, 2027. State Medicaid agencies can join the model beginning in May 2026, expanding coverage to millions who currently cannot afford these medications.
Read full story →GLP-1 Weight Loss Users Face More Social Stigma Than Those Who Diet
TLDR: New research finds that people who lose weight using GLP-1 drugs like Ozempic may actually face more social judgment than those who lose weight through diet and exercise. The stigma appears rooted in the perception that these medications are an easy way out, creating a social double bind for patients.
Read full story →Wednesday — Wednesday, May 6, 2026
4 articlesFDA Proposes Permanent End to Large-Scale Compounding of GLP-1 Drugs
TLDR: The FDA announced a proposal to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk substances list, citing no clinical need. A public comment period is open through June 29, 2026. The move would effectively shut down large-scale compounding pharmacies that have supplied lower-cost GLP-1 alternatives.
Read full story →Semaglutide Linked to 44% Lower Risk of Depression and 38% Reduction in Anxiety Disorders
TLDR: A new study found that patients taking semaglutide experienced 44% fewer depression diagnoses and 38% fewer anxiety disorders compared to non-users. Psychiatric-related hospital visits and sick leave also dropped by 42% while on the medication. Researchers say the findings add to growing evidence that GLP-1s may have significant mental health benefits.
Read full story →Weight Stigma Study: GLP-1 Users Face More Social Judgment Than Those Who Diet
TLDR: New research reveals that people who lose weight on GLP-1 medications face more social stigma than those who lose weight through diet and exercise. The stigma appears rooted in perceptions that medication is an easy shortcut rather than a legitimate treatment. Researchers say this bias may discourage people from seeking effective obesity care.
Read full story →Semaglutide Associated With Increased Optic Nerve Injury Risk, New Analysis Finds
TLDR: An analysis of over 30 million FDA adverse event reports found that semaglutide drugs were the only medications strongly associated with optic nerve injury (NAION), with Wegovy producing the strongest safety signal. Notably, tirzepatide (Mounjaro/Zepbound) did not show the same risk. Ongoing litigation and updated FDA safety labeling are expected.
Read full story →Tuesday — Tuesday, May 5, 2026
4 articlesFDA Proposes Permanent End to Mass GLP-1 Compounding, Citing No Clinical Need
TLDR: The FDA has proposed removing semaglutide, tirzepatide, and liraglutide from its 503B outsourcing facility bulk drug substances list, effectively ending large-scale compounding of GLP-1 medications. The agency said there is no clinical need for compounded versions now that the national shortage has been resolved. A public comment period runs through June 29, 2026.
Read full story →Semaglutide Linked to 44% Lower Depression Risk and 38% Reduction in Anxiety
TLDR: A new study found that GLP-1 use — particularly semaglutide (Ozempic, Wegovy) — was associated with significantly fewer psychiatric hospital visits, a 44% lower risk of depression, and a 38% reduced risk of anxiety disorders. Researchers also observed reduced sickness absence among users, suggesting mental health benefits extend beyond weight loss.
Read full story →FDA to Restrict Ingredients in Compounded GLP-1s and Crack Down on Misleading Ads
TLDR: Alongside its compounding proposal, the FDA announced it will restrict the use of certain added ingredients in mass-marketed compounded GLP-1 products and take enforcement action against providers making misleading advertising claims. The crackdown targets compounders that have marketed their products as equivalent or superior to brand-name GLP-1 medications.
Read full story →New Wegovy Pill Offers Needle-Free Weight Loss But May Not Work for Everyone
TLDR: The oral Wegovy pill, approved by the FDA in December 2025, is gaining attention as a needle-free alternative to injections — but clinicians note it requires strict dosing protocols and may be less effective for patients with certain GI conditions. Higher doses are priced at $300 per month, raising accessibility questions.
Read full story →Monday — Monday, May 4, 2026
4 articlesFDA Proposes to Permanently Exclude Semaglutide and Tirzepatide from 503B Compounding List
TLDR: The FDA proposed on April 30, 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list, finding no clinical need for large-scale compounding of these drugs. If finalized, the rule would shut down bulk compounding by 503B facilities and significantly curtail telehealth platforms that have relied on compounded GLP-1s. A public comment period is open through June 29, 2026.
Read full story →Scientists Identify Genetic Cause of GLP-1 Resistance in 10% of Patients
TLDR: A new study found that roughly 10% of people carry genetic variants that cause GLP-1 resistance, meaning their bodies naturally produce elevated levels of the GLP-1 hormone but fail to respond to it properly. This discovery may explain why some patients see minimal results from drugs like Ozempic and Wegovy despite adequate dosing.
Read full story →GLP-1 Weight Loss May Accelerate Facial Aging, Researchers Warn
TLDR: Rapid fat loss from GLP-1 medications like semaglutide and tirzepatide can accelerate visible facial aging through loss of facial volume and reduced collagen production — a phenomenon now widely called Ozempic face. Clinicians note that as much as 40% of weight lost on GLP-1s can be lean tissue, amplifying these aesthetic effects.
Read full story →Over 3,000 Ozempic Lawsuits Pending Over Gastroparesis and Vision Injuries
TLDR: More than 3,000 product liability lawsuits against Novo Nordisk and Eli Lilly are now consolidated in two MDLs in the Eastern District of Pennsylvania, covering claims of gastroparesis and NAION, a rare vision condition. The litigation underscores the ongoing scrutiny of long-term GLP-1 side effects as usage continues to grow.
Read full story →Sunday — Sunday, May 3, 2026
4 articlesFDA Moves to Permanently End Compounded GLP-1 Medications
TLDR: The FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug list, citing no clinical need for compounded versions. A public comment period is open through June 29, 2026. The move would effectively shut down the compounding pharmacies and telehealth firms that have supplied millions with cheaper alternatives.
Read full story →CMS Launches Medicare GLP-1 Bridge: $50/Month Starting July 2026
TLDR: The Centers for Medicare and Medicaid Services announced the Medicare GLP-1 Bridge, giving eligible Part D beneficiaries access to GLP-1 weight-loss medications for just $50 per month from July 1, 2026 through December 31, 2027. The voluntary demonstration aims to reduce cost barriers for Medicare enrollees with obesity.
Read full story →Louisiana Bill Would Expand Medicaid Coverage for Ozempic, Wegovy, and Mounjaro
TLDR: Louisiana Senate Bill 433 would allow qualified Medicaid recipients to use GLP-1 medications to treat obesity, one of the state's most pressing public health challenges. Louisiana has one of the highest adult obesity rates in the nation at roughly 39-40%, well above the national average.
Read full story →GLP-1 Weight Loss May Accelerate Facial Aging, Researchers Warn
TLDR: A newly identified side effect of GLP-1 medications is accelerated facial aging, with rapid fat loss leading to hollowed cheeks, deepened wrinkles, and sagging skin. Clinicians are advising patients to be aware of the cosmetic changes that can accompany significant weight loss on these drugs.
Read full story →Saturday — Saturday, May 2, 2026
3 articlesJohns Hopkins Study: GLP-1 Drugs Cut 5-Year Cardiovascular and Kidney Risks in Type 1 Diabetes Patients
TLDR: Researchers at the Johns Hopkins Bloomberg School of Public Health analyzed electronic health records from roughly 175,000 U.S. adults with type 1 diabetes and found that those who started GLP-1 receptor agonists like semaglutide or tirzepatide had a 15% lower five-year risk of major cardiovascular events and a 19% lower risk of end-stage kidney disease compared with non-users. The analysis also estimated 21% lower heart attack risk, 16% lower all-cause mortality, and — addressing long-standing safety concerns in T1D — 18% lower risk of severe hypoglycemia hospitalization and 17% lower risk of diabetic ketoacidosis hospitalization. GLP-1 drugs are not currently FDA-approved for type 1 diabetes, and the authors say their findings should prompt randomized trials in this population.
Read full story →Endoscopic 'Gut Reset' Procedure Cuts Post-GLP-1 Weight Regain by 40% in Sham-Controlled Trial
TLDR: Data presented at Digestive Disease Week (DDW) 2026 show that duodenal mucosal resurfacing — an endoscopic procedure that uses controlled heat to ablate and regenerate the lining of the duodenum — significantly slowed weight regain in patients who stopped tirzepatide. Among 45 patients who had previously lost at least 15% of body weight on the GLP-1, the sham group regained 40% more weight than the treatment group at six months, with the gap widening over time. The larger 300-patient pivotal REMAIN-1 trial is fully enrolled, with topline data expected in Q4 2026 and a potential FDA marketing submission to follow.
Read full story →'Ozempic Personality' Emerges as a Reported GLP-1 Side Effect: Mild Anhedonia and Emotional Blunting
TLDR: Doctors and patients are increasingly describing a clinical pattern dubbed 'Ozempic personality' — a mild form of anhedonia in which GLP-1 medications appear to dull the brain's reward response not only to food but also to activities like music, hobbies, sex, and socializing. Researchers including obesity expert Daniel Drucker hypothesize that GLP-1 receptor agonists tone down brain regions tied to pleasure and dopamine signaling. Reports remain uncommon and most cases resolve when the dose is reduced, and a separate large analysis still found semaglutide associated with a lower risk of worsening depression, anxiety, substance use disorder, and self-harm.
Read full story →Friday — Friday, May 1, 2026
3 articlesFDA Proposes Removing Semaglutide, Tirzepatide, and Liraglutide from 503B Compounding List
TLDR: On April 30, 2026, the FDA announced a proposed determination that there is no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk drug substances under section 503B. If finalized, the rule would block large compounding facilities that supply many telehealth platforms from producing bulk versions of the major GLP-1 drugs. The agency is accepting public comments through June 29, 2026, and the proposal does not affect 503A pharmacies that fill individual patient prescriptions.
Read full story →Lilly Q1 2026 Earnings Beat Big; Mounjaro and Zepbound Drive Raised Full-Year Guidance
TLDR: Eli Lilly reported Q1 2026 revenue of $19.8 billion (up 56% year-over-year) and adjusted EPS of $8.55, well above the $6.79 consensus. Mounjaro global revenue rose 125% to $8.7 billion and U.S. Zepbound revenue grew 79% to $4.1 billion despite lower realized prices. Lilly raised full-year 2026 guidance to $82-$85 billion in revenue (from $80-$83 billion) and $35.50-$37.00 in adjusted EPS (from $33.50-$35.00).
Read full story →Repositioning GLP-1 Drugs for Neurologic Disease: Mixed Phase 3 Signals in Alzheimer's, Stronger Evidence in Parkinson's
TLDR: A new clinical review summarizes the state of GLP-1 receptor agonists in neurodegenerative disease, noting that Novo Nordisk's EVOKE phase 3 trials of semaglutide failed to slow cognitive decline in early Alzheimer's and the ELAD 2 trial of liraglutide did not significantly slow brain metabolism decline. Parkinson's disease evidence has been more consistent, with exenatide and lixisenatide showing motor function benefits on UPDRS-III scores in the ON state, though the pegylated exendin NLY01 missed its primary endpoint. The class is not yet indicated for either condition.
Read full story →Thursday — Thursday, April 30, 2026
4 articlesEli Lilly Reports Q1 2026 Earnings; Investors Watch Mounjaro, Zepbound, and Foundayo Trajectories
TLDR: Eli Lilly is releasing its first-quarter 2026 financial results pre-market on April 30, with a 10 a.m. ET conference call to follow. Wall Street is watching three GLP-1 storylines in particular: continued growth of Mounjaro and Zepbound (which together generated $36.5 billion in 2025 sales), gross-to-net pricing pressure on Zepbound, and management commentary on the rocky early launch of the new oral GLP-1 pill Foundayo (orforglipron) following weak IQVIA prescription data through April.
Read full story →Provocative New Paper Argues GLP-1 May Not Be Necessary for Effective Weight Loss
TLDR: Richard DiMarchi and Matthias Tschöp, two of the scientists whose work seeded the modern obesity-drug class, published a peer-reviewed paper proposing that activating only the GIP and glucagon receptors, with no GLP-1 component, can match GLP-1-containing drugs for weight loss in rodents and monkeys. Funded by BlueWater Biosciences, the experimental molecule reportedly avoids the nausea and vomiting common to current treatments. The findings are preclinical and have yet to be confirmed in humans.
Read full story →FormBlends Releases 2026 State of Peptides Report Mapping RFK-Era HHS Shifts on GLP-1 Access
TLDR: Telehealth platform FormBlends published its 2026 State of Peptides and GLP-1 Regulation report on April 28, charting how the Kennedy-led HHS, the FDA Center for Drug Evaluation and Research, and the obesity pipelines at Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Roche are reshaping legal access to weight-management and metabolic peptides. The 2026 HHS budget includes new language on "evidence review for therapeutic peptides," suggesting Category 2 designations on compounds like BPC-157, CJC-1295, and Sermorelin may be reassessed before 2027.
Read full story →APhA2026 Highlights GLP-1 Therapies Rewriting Metabolic Disease Care Across Specialties
TLDR: Coverage from the American Pharmacists Association 2026 annual meeting underscores how rapidly GLP-1 receptor agonists are crossing specialty lines, with new and expanded indications now spanning cardiovascular risk reduction, chronic kidney disease, MASH/liver fibrosis, and obstructive sleep apnea. Pharmacists at the meeting flagged growing complexity around adherence support, gross-to-net pricing changes, and patient counseling as the field shifts from injectables to a mixed oral-and-injectable landscape including oral Wegovy and Foundayo.
Read full story →Wednesday — Wednesday, April 29, 2026
4 articlesLilly's Foundayo Faces Weak Early Uptake as Q1 Earnings Loom This Week
TLDR: Early IQVIA prescription data shows Eli Lilly's new oral GLP-1 pill Foundayo (orforglipron) is significantly trailing Novo Nordisk's oral Wegovy in the weeks since its April 6 launch, sending LLY shares lower while NVO stock has climbed toward $41. Investors are watching Lilly's Q1 earnings report on April 30 for management commentary on the launch trajectory and any revised guidance on the oral obesity market.
Read full story →Novo Nordisk's Oral Semaglutide Hits Primary Endpoint in First Pediatric GLP-1 Trial
TLDR: Topline results from the Phase 3a PIONEER TEENS trial showed oral semaglutide delivered a statistically significant 0.83% greater HbA1c reduction versus placebo at week 26 in 132 children and adolescents aged 10 to 17 with type 2 diabetes. Novo Nordisk plans to file for pediatric label expansion in the U.S. and EU in the second half of 2026, which would make oral semaglutide the first oral GLP-1 receptor agonist approved for this population.
Read full story →FuturHealth Among First Telehealth Providers to Offer Lilly's Oral GLP-1 Foundayo
TLDR: Telehealth platform FuturHealth announced it is among the first providers to add Eli Lilly's newly approved oral GLP-1 Foundayo (orforglipron) to its weight-loss program offerings. The move expands non-injectable GLP-1 access beyond LillyDirect and signals the start of broader distribution through digital health channels as the pill's commercial launch ramps.
Read full story →GLP-1 Drugs Cut Heart and Kidney Risk in Type 1 Diabetes Patients, Johns Hopkins Finds
TLDR: A Johns Hopkins analysis of electronic health records from roughly 175,000 type 1 diabetes patients found that GLP-1 receptor agonists like semaglutide and tirzepatide reduced the five-year risk of major cardiovascular events by 15% and end-stage kidney disease by 19%. The findings strengthen the case for off-label use of GLP-1 therapies in type 1 diabetes, a population in which the drugs are not currently approved for cardiovascular or renal protection.
Read full story →Tuesday — Tuesday, April 28, 2026
4 articlesCMS Extends Medicare GLP-1 Bridge Through 2027, Delays BALANCE Obesity Model
TLDR: The Centers for Medicare & Medicaid Services announced it will extend the Medicare GLP-1 Bridge program — providing $50 monthly copays for Wegovy and Zepbound — through the end of 2027, while delaying the larger BALANCE model that had been scheduled to launch on January 1, 2027. The decision keeps a temporary access path open for eligible Medicare beneficiaries but pushes off the broader, permanent obesity-drug coverage framework.
Read full story →NEJM Analysis Warns GLP-1 Boom Could Surface 420,000 New Eating Disorder Cases
TLDR: A New England Journal of Medicine perspective published over the weekend estimates that if roughly one in eight Americans takes a GLP-1, more than 420,000 people could develop an eating disorder linked to the drugs. The authors urge prescribers to screen patients for disordered eating before starting Wegovy, Ozempic, or Zepbound and call for stronger clinical guardrails as use scales.
Read full story →23andMe Genetic Study Pinpoints Why GLP-1 Drugs Work Better — and Worse — in Some Patients
TLDR: Analyzing data from nearly 28,000 23andMe users on GLP-1 therapy, researchers identified a variant in the GLP1R gene that is significantly associated with greater weight loss, while carriers of certain other variants were 83% more likely to experience vomiting on tirzepatide. The findings could help explain why roughly one in ten patients respond poorly to these drugs and may inform future genetic screening before prescribing.
Read full story →Tirzepatide Linked to 62% Lower Death Risk in Heart Patients After PCI Procedures
TLDR: A new analysis of 1,281 patients who underwent percutaneous coronary intervention found a 62% lower mortality rate among those taking tirzepatide, the active ingredient in Mounjaro and Zepbound. The data add to a growing body of evidence — including the SUMMIT trial in heart failure with preserved ejection fraction — that tirzepatide's cardiovascular benefits may extend well beyond weight loss.
Read full story →Monday — Monday, April 27, 2026
4 articlesNovo Nordisk's Wegovy HD Now Available Nationwide at $399 Per Month
TLDR: Novo Nordisk announced that Wegovy HD, the higher-dose weekly semaglutide injection at 7.2 mg, is now available at all U.S. pharmacies and telehealth platforms for $399 per month. The shot delivered 20.7% mean weight loss in the STEP UP trial, with roughly one in three participants losing 25% or more of their body weight.
Read full story →Millions of Patients Are Losing Commercial Insurance Coverage for GLP-1 Weight-Loss Drugs
TLDR: An NPR investigation finds that roughly 12 million Americans each lost commercial insurance coverage for Wegovy and Zepbound between 2025 and 2026 as employers scaled back benefits due to high costs. The access gap is widening just months before Medicare is set to begin covering GLP-1s for obesity in July.
Read full story →GLP-1 Adherence Drops Sharply at Six Months in Real-World Medicaid Study
TLDR: A real-world study of Medicaid patients found that persistence with GLP-1 medications for obesity declined substantially within six months of starting treatment, with many patients stopping due to cost sharing, access barriers, and side effects. The findings raise concerns about whether coverage expansions alone will translate to durable health outcomes without stronger support structures.
Read full story →Major Nutrition and Obesity Societies Issue Joint Nutritional Guidelines for Patients on GLP-1 Therapy
TLDR: A joint advisory from four leading organizations — including the American Society for Nutrition and The Obesity Society — establishes nutritional priorities for people taking GLP-1 medications. The guidance recommends higher protein intake, routine micronutrient monitoring, and structured behavioral support to reduce the risk of muscle loss and nutritional deficiencies during treatment.
Read full story →Sunday — Sunday, April 26, 2026
4 articlesSimple Gut Reset Procedure May Stop Weight Gain After Stopping Ozempic or Wegovy
TLDR: Researchers found that a minimally invasive outpatient procedure called duodenal mucosal resurfacing may help people maintain weight loss after stopping GLP-1 drugs. The first blinded, randomized, sham-controlled trial showed it can prevent the rebound weight gain that affects roughly 70% of people who discontinue medications like Ozempic or Wegovy.
Read full story →Scientists Discover Why Ozempic Does Not Work for About 10% of Users
TLDR: A new study identified a genetic-based condition called GLP-1 resistance in roughly 10% of patients, explaining why some people see little benefit from semaglutide-based drugs. These individuals produce higher levels of the GLP-1 hormone naturally but do not respond to it properly, making standard dosing ineffective.
Read full story →Quitting a GLP-1 and Starting Again: What Patients and Doctors Need to Know
TLDR: Many patients are cycling on and off GLP-1 medications like Ozempic and Wegovy due to cost, side effects, or supply issues — a pattern doctors say carries real risks. Studies suggest stopping and restarting can accelerate fat regain while lean muscle loss accumulates over time, compounding metabolic harm.
Read full story →GLP-1 Access Is Tightening as FDA Enforcement Narrows Compounding Sources
TLDR: FDA enforcement actions against compounding pharmacies have significantly reduced the number of legal sources for compounded semaglutide and tirzepatide in 2026. Telehealth platforms are raising prices and patients who started treatment on compounded versions face fewer options as the market shifts toward brand-name medications.
Read full story →Saturday — Saturday, April 25, 2026
4 articlesTrump Administration Shelves Medicare GLP-1 Pilot, Will Fund Coverage Directly
TLDR: The Trump administration is indefinitely delaying its Medicare pilot program to cover weight-loss drugs after insurers raised cost concerns. Instead of requiring Part D plans to fund coverage, CMS will extend the GLP-1 Bridge program through 2027, giving eligible Medicare beneficiaries access to Wegovy and Zepbound at a $50/month copay paid by taxpayers.
Read full story →Novo Nordisk Oral Semaglutide Shows Promise for Teens With Type 2 Diabetes
TLDR: Novo Nordisk announced positive results from the PIONEER TEENS trial evaluating oral semaglutide in adolescents aged 10-17 with type 2 diabetes. The drug demonstrated superior HbA1c reduction versus placebo with an acceptable safety profile, and the company expects to file for regulatory label expansion in the US and EU in the second half of 2026.
Read full story →Minimally Invasive Gut Procedure May Help Prevent Weight Regain After Stopping GLP-1s
TLDR: Research presented at Digestive Disease Week 2026 suggests a minimally invasive outpatient gut procedure may help people avoid the significant weight regain that typically follows stopping GLP-1 medications. Around 70% of patients who discontinue drugs like Ozempic or Wegovy regain most of their lost weight within 18 months.
Read full story →Scientists Identify Genetic Reason Ozempic Does Not Work for About 10% of Users
TLDR: A new study found that roughly 10% of people have genetic variants that cause GLP-1 resistance, meaning their bodies produce elevated levels of the GLP-1 hormone but fail to respond to it normally. This discovery may explain why some patients see little to no weight loss or glycemic benefit from semaglutide-based drugs.
Read full story →Friday — Friday, April 24, 2026
5 articlesGLP-1 Price Deal Hits Snag as Medicare Delays Program Implementation
TLDR: The Trump administration reached Most-Favored-Nation pricing agreements with Eli Lilly and Novo Nordisk that would drop Wegovy and Zepbound to roughly $345-$350/month through TrumpRx and $245 for Medicare. However, a key piece of the deal fell apart this week when Medicare delayed implementing coverage for GLP-1s for obesity.
Read full story →Semaglutide Fails Two Large Alzheimer's Disease Trials
TLDR: Novo Nordisk reported that semaglutide showed no slowing of disease progression versus placebo in two large, randomized controlled trials in people with Alzheimer's disease. The disappointing results close off one of the most anticipated potential new uses of GLP-1 drugs beyond metabolic disease.
Read full story →Oral Semaglutide Shows Promise for Children and Teens with Type 2 Diabetes
TLDR: Novo Nordisk announced positive phase 3 results from the PIONEER TEENS trial, showing oral semaglutide significantly reduced blood sugar versus placebo in children and adolescents aged 10-17 with type 2 diabetes. The company plans to seek regulatory approval for a pediatric label expansion in the US and EU later this year.
Read full story →Gut Procedure May Prevent Weight Regain After Stopping GLP-1 Drugs
TLDR: A minimally invasive outpatient procedure called duodenal mucosal resurfacing may offer a lasting way to maintain weight loss after discontinuing GLP-1 medications. Researchers say the gut reset works by remodeling the intestinal lining, potentially addressing the root cause of weight regain that affects about 70% of patients who stop these drugs.
Read full story →Scientists Identify Why GLP-1 Drugs Do Not Work for About 10% of Users
TLDR: A new study found that specific genetic variants cause GLP-1 resistance in roughly 10% of people, explaining why some patients see little to no benefit from semaglutide and tirzepatide. These individuals naturally produce higher levels of the GLP-1 hormone but do not respond to it properly, pointing toward a need for personalized obesity treatment strategies.
Read full story →Thursday — Thursday, April 23, 2026
4 articlesStanford Scientists Discover Natural Molecule That Mimics GLP-1 Effect Without Nausea or Muscle Loss
TLDR: Stanford researchers identified a naturally occurring molecule called BRP that suppresses appetite by acting directly on brain regions controlling hunger, producing weight loss comparable to GLP-1 drugs in animal models but without nausea, vomiting, or muscle loss. The findings suggest a potential new class of obesity treatments that could benefit the subset of patients who discontinue GLP-1 therapy due to side effects.
Read full story →Pioneers of GLP-1 Drugs Propose Ditching the GLP-1 Receptor as a Target for Next-Generation Obesity Treatments
TLDR: Richard DiMarchi and Matthias Tschop, researchers whose work underpinned today's GLP-1 blockbusters, now argue that GLP-1 receptor activation may not be essential for effective obesity treatment. Their experimental compound targets GIP and glucagon receptors without a GLP-1 component and has shown equivalent weight loss in preclinical models with improved tolerability, potentially opening a new route for patients who cannot tolerate semaglutide or tirzepatide.
Read full story →GLP-1 Drugs Show Growing Promise Across Neurological Diseases, Despite Alzheimer Trial Setback
TLDR: A comprehensive review finds that while semaglutide failed to slow Alzheimer progression in the Phase 3 EVOKE trials, GLP-1 receptor agonists are demonstrating real potential in Parkinson disease and may have neuroprotective effects through reduced neuroinflammation and improved metabolic signaling. Clinicians are watching several ongoing Phase 3 trials that could establish GLP-1s as neurological treatments within the next few years.
Read full story →Oral GLP-1 Pills Are Reshaping Obesity Care and Medical Training, AAMC Analysis Finds
TLDR: The Association of American Medical Colleges examines how FDA-approved oral GLP-1 pills from Novo Nordisk and Eli Lilly are lowering the injection-aversion barrier and shifting obesity management toward primary care. Medical schools are updating residency curricula as GLP-1 prescribing moves from specialist territory to a routine competency expected of all clinicians.
Read full story →Wednesday — Wednesday, April 22, 2026
5 articlesFDA Compounding Deadline Hits Today: Small 503A Pharmacies Must Stop Producing Semaglutide
TLDR: April 22 marks the FDA enforcement deadline for state-licensed 503A compounding pharmacies to halt production of semaglutide, with larger 503B outsourcing facilities given until May 22 to wind down. The phased shutdown closes a loophole that flourished during the shortage and is expected to push price-sensitive patients toward branded Wegovy and Ozempic, telehealth weight-loss programs, or oral alternatives like the newly approved Foundayo.
Read full story →Mass General Brigham Real-World Study Finds Tirzepatide and Semaglutide Both Cut Heart Attack and Stroke Risk
TLDR: An analysis of nearly one million adults published in Nature Medicine found semaglutide cut the combined risk of heart attack and stroke by 18 percent versus sitagliptin, while tirzepatide produced a 13 percent reduction in major cardiovascular events versus dulaglutide. Head-to-head, the two drugs delivered comparable cardioprotection, reinforcing both as foundational options for patients with type 2 diabetes and elevated cardiometabolic risk.
Read full story →Lilly Foundayo Now Shipping Through LillyDirect and Retail Pharmacies After FDA Nod for Oral GLP-1 Pill
TLDR: Foundayo (orforglipron), the first once-daily oral GLP-1 that can be taken any time of day without food or water restrictions, is now shipping nationwide through LillyDirect and rolling out across retail pharmacies and telehealth providers. Commercial-insured patients can pay $25 a month with the Lilly savings coupon, while cash payers face $149 to $349 depending on dose, opening a lower-friction onramp for patients who have avoided injectables.
Read full story →Medicare GLP-1 Bridge to Cap Wegovy, Zepbound, and Foundayo Copays at $50 Starting July 1
TLDR: CMS confirmed the Medicare GLP-1 Bridge will launch July 1 and run through December 2027, capping Part D copays at $50 for Foundayo, Wegovy injection and tablets, and Zepbound for eligible obesity patients. The temporary program bridges the gap until the broader BALANCE Model expands GLP-1 coverage in Medicaid in May 2026 and Medicare Part D in January 2027.
Read full story →Stanford Researchers Identify Genetic GLP-1 Resistance That May Explain Why Drugs Fail in 1 in 10 Patients
TLDR: A new Stanford-led study in Genome Medicine pinpointed gene variants that may explain why roughly 10 percent of patients see little response to Ozempic, Wegovy, and similar GLP-1 receptor agonists. The patients show elevated endogenous GLP-1 hormone levels but blunted receptor signaling, hinting at a future where genetic screening guides who is likely to benefit from injectable GLP-1s versus alternative therapies.
Read full story →Stay Informed
Get the GLP-1 Insider Brief
Exclusive provider discounts, healthy living guides for your GLP-1 journey, and the latest breakthroughs in peptide science — delivered free.
No spam. Unsubscribe any time.